<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031612</url>
  </required_header>
  <id_info>
    <org_study_id>AB2009SEIN</org_study_id>
    <nct_id>NCT04031612</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Database</brief_title>
  <acronym>NEOADJ</acronym>
  <official_title>Prospective and Retrospective Neoadjuvant Breast Cancer Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NEOADJ Database base contains data collected during the regular clinical patient
      management (sociodemographic, clinical, pathological, radiological, biological, disease
      evolution...). This database allows easy access to information in a centralized and
      structured way.

      This cohort is used to gather insights for research purposes. All data collected come from
      medical files of patients managed at Centre Georges Francois Leclerc, Dijon, France.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2009</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival and evolution over years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of patient and treatment characteristics</measure>
    <time_frame>5 years</time_frame>
    <description>Collection of patient and treatment characteristics over years, to set up prospective and retrospective studies</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Neoadjuvant Treatment in Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Breast Cancer</arm_group_label>
    <description>Patients undergoing neoadjuvant therapy for breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant therapy</intervention_name>
    <description>Neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Breast Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non metastatic breast cancer who received neoadjuvant chemotherapy prior to
        tumor surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women followed for breast cancer in Georges Francois Leclerc Center

          -  Neoadjuvant chemotherapy

          -  Age &gt;= 18

        Exclusion Criteria:

          -  Males

          -  Metastatic breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AURELIE BERTAUT, MD, PHD</last_name>
    <phone>+33 3 80 73 77 84</phone>
    <email>ABertaut@cgfl.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Methodology, Biostatistics and Data Management Unit</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AURELIE BERTAUT</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer; Breast, Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

